Source link : https://www.newshealth.biz/health-news/anti-cd19-monoclonal-antibody-shows-positive-results-in-myasthenia-gravis/
SAVANNAH, Ga. — Inebilizumab (Uplizna) had clinically meaningful efficacy and a favorable safety profile among people with generalized myasthenia gravis (gMG), topline data from the MINT trial showed. The anti-CD19 monoclonal antibody was effective in a combined population with acetylcholine receptor autoantibody-positive (AChR+) or muscle-specific kinase autoantibody-positive (MuSK+) gMG, said Richard Novak, MD, MS, of […]
Author : News Health
Publish date : 2024-10-15 20:40:09
Copyright for syndicated content belongs to the linked Source.
Categories